Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alon...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Hematol Oncol
Huvudupphovsmän: Cortes, Jorge E., Heidel, Florian H., Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Candoni, Anna, Leber, Brian, Sekeres, Mikkael A., Pollyea, Daniel A., Ferdinand, Roxanne, Ma, Weidong Wendy, O’Brien, Thomas, O’Connell, Ashleigh, Chan, Geoffrey, Heuser, Michael
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2020
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362563/
https://ncbi.nlm.nih.gov/pubmed/32664995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00929-8
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk